ArticleLeukemia2007
MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course.
Article in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 98 citations in OpenAlex.
- Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial.Hematological oncology · 2019Trial
- Field-testing the MALT-IPI in a single-center real-world cohort of patients with extranodal marginal zone lymphoma.Blood advances · 2026Article
- Primary giant mucosa-associated lymphoid tissue lymphoma of the lower lip: a case report and literature review.BMC oral health · 2025Review
- Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.Frontiers in immunology · 2024Review
- Not Everything That Ulcerates Is Crohn's Disease.GE Portuguese journal of gastroenterology · 2023Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Nomogram model predicting the overall survival for patients with primary gastric mucosa-associated lymphoid tissue lymphoma.World journal of gastrointestinal oncology · 2023Article
- Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.Therapeutic advances in medical oncology · 2023Review
- MALT lymphoma of the sublingual gland: A case report with current overview of diagnostic and therapeutic strategies.Clinical case reports · 2022Article
- Review
- The Biology of Ocular Adnexal Marginal Zone Lymphomas.Cancers · 2022Review
- Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas.World journal of gastrointestinal oncology · 2022Review
- Thymic Extranodal Marginal-Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: Pathological Features,Frontiers in medicine · 2022Article
- MALT Lymphoma Presenting with Peripheral Ulcerative Keratitis.International medical case reports journal · 2022Article
- Recent Advances in the Genetic of MALT Lymphomas.Cancers · 2021Review
- Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report.BMC oral health · 2021Article
- Genetic Characterization and Clinical Features ofCancers · 2021Article
- Imaging of head and neck mucosa-associated lymphoid tissue lymphoma (MALToma).Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Review
- Article
- What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments.Therapeutic advances in medical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MALT lymphoma, especially of extragastric origin, is thought to be associated with an underlying autoimmune disease (AD) in a significant proportion of patients. No systematic assessment of the clinical characteristics of MALT lymphoma arising in AD as opposed to patients without AD has been performed so far. Therefore, all patients diagnosed and treated for MALT lymphoma at our institution have prospectively undergone routine clinical and serological assessment for AD since 1997. In total, 158 patients were available for analysis, and 61 out of 158 patients (39%) were diagnosed with an underlying AD. Patients with AD were predominantly women and significantly younger at lymphoma diagnosis (56 versus 67 years, P=0.004), with a significantly higher rate of extragastric lymphomas (P=0.012). Furthermore, lymphomas in these patients showed a lower frequency of trisomy 3 (P=0.04) and a significantly lower response rate to Helicobacter pylori eradication therapy in the case of gastric lymphomas (P=0.03). All other parameters including estimated median time to relapse were comparable between both groups. Our data suggest that patients with AD develop MALT lymphoma significantly earlier in life. The clinical course, however, does not appear to be adversely influenced by the presence of AD, as neither rate of relapse nor times to relapse or survival are significantly different.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.